UnitedHealth Group Incorporated

UnitedHealth Group Incorporated (UNH) Market Cap

UnitedHealth Group Incorporated has a market capitalization of $362.78B.

Price: $399.47

3.00 (0.76%)

Market Cap: 362.78B

NYSE · time unavailable

CEO: Stephen J. Hemsley

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 1984-10-17

Website: https://www.unitedhealthgroup.com

UnitedHealth Group Incorporated (UNH) - Company Information

Market Cap: 362.78B|Sector: Healthcare

Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage and well-being services to individuals age 50 and older addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance and health care programs; health and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.

Analyst Sentiment

79%
Strong Buy

From 28 Active Polls

1Y Forecast: $417.25

▲ +4.5% Potential Upside

Consensus Target Metrics

Low Bound

$345

Median

$417

High Bound

$492

Average

$417

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$417.25
▲ +4.45% Upside
Low Target
$345.00
-14% Risk
Median Target
$417.00
4% Mid
High Target
$492.00
23% Max
Consensus
Buy
43 / 52 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Historical valuation matrix unavailable.

UNH Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$399.47
Intrinsic Value$654.53
Market Alignment
Undervalued by 63.8%relative to calculated intrinsic value
9.00%
Exp: 9%9%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$41.09B
Perpetuity TV Value$773.21B
Discounted TV (PV)$326.61B
TV Weighting %61.9%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 UNITEDHEALTH GROUP INC (UNH) — Investment Overview

🧩 Business Model Overview

UnitedHealth Group operates an integrated health services platform spanning insurance and healthcare services. On the payer side, UnitedHealthcare earns premiums and is accountable for member outcomes and costs through managed-care contracting (with physicians, hospitals, and other providers) and benefit plan administration. On the services side, Optum supplies capabilities across pharmacy benefit management, care delivery, analytics, and other healthcare services, which feed into utilization management and care coordination.

The economic logic is that scale in enrollment and provider contracting improves cost and care efficiency, while Optum’s services supply tools (clinical management, analytics, and pharmacy leverage) that can tighten medical cost trend. This integration creates a value chain where underwriting discipline and service execution reinforce each other, strengthening member retention and employer plan stickiness.

💰 Revenue Streams & Monetisation Model

Revenue is primarily driven by:

  • Premiums/capitation and administrative fees from health plans (payer segment). This stream is largely recurring, tied to membership and benefit design.
  • Fees for healthcare services across Optum (services segment), including pharmacy benefit administration and care delivery-related revenues. This mix tends to be more recurring and contract-driven than pure one-time transactions.

Margin drivers center on:

  • Medical cost management (discipline around utilization, network design, and care pathways), which influences profitability in the payer segment.
  • Pharmacy and services efficiency (formulary strategy, pharmacy network leverage, and operational throughput), which influences incremental margins at Optum.
  • Operating leverage from shared analytics and workflow capabilities across the integrated ecosystem.

🧠 Competitive Advantages & Market Positioning

UNH’s core moat is an integrated ecosystem that combines payer scale with high-value services, supported by switching costs, data/analytics barriers, and cost advantages.

  • Integrated ecosystem (integrated ecosystem moat): Optum’s clinical and operational tools—analytics, pharmacy management, and care delivery—improve utilization control and care coordination. Competitors that operate as standalone payers or standalone services providers face higher coordination costs and less end-to-end optimization.
  • Switching costs and contracting inertia (switching costs moat): Large employers, government programs, and provider networks develop operational and reimbursement alignment with existing plan designs. Changing vendors requires renegotiation, administrative reconfiguration, and performance rebuilding, which tends to support retention.
  • Cost and scale advantages (cost advantages moat): Enrollment scale enhances negotiating leverage with providers and pharmacies. The ability to manage risk and trend through analytics and targeted care programs supports more consistent earnings quality than less diversified peers.
  • High barriers to entry (barriers through scale, compliance, and risk management): Building the actuarial, regulatory, and operational infrastructure to manage member risk at scale is non-trivial, especially within complex government programs.

Competitive benchmarking (industry focus vs. peers):

  • CVS Health (payer + PBM + retail/health services exposure): Like UNH, CVS spans multiple healthcare functions. UNH’s differentiation is the emphasis on an end-to-end managed-care ecosystem with Optum’s analytics and care delivery integrated into the payer workflow.
  • Humana (predominantly managed care): Humana’s strengths concentrate more heavily in insurance execution and Medicare-focused membership. UNH’s services footprint adds another channel to influence utilization and margins beyond underwriting alone.
  • Cigna (managed care + services footprint): Cigna operates across payer and services. UNH’s scale across services—particularly pharmacy and analytics-driven care management—supports a broader platform approach to cost and outcomes management.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by secular healthcare demand and structural shifts in how care is delivered and paid:

  • Demographic tailwinds: Aging populations increase enrollment in Medicare and raise the need for chronic disease management and coordinated care.
  • Ongoing shift toward managed care and value-based approaches: Payers that can manage utilization risk and standardize care pathways typically benefit as reimbursement moves away from pure fee-for-service incentives.
  • Expansion of Optum services into higher-value segments: Growth opportunities exist in care delivery, pharmacy services, and analytics-driven programs that reduce avoidable utilization while improving care quality.
  • Healthcare spending complexity: Higher care complexity strengthens demand for administrative efficiency, clinical management, and outcomes measurement—areas where integrated players can deploy data and operating workflows at scale.

⚠ Risk Factors to Monitor

  • Regulatory and reimbursement risk: Changes to Medicare Advantage and Medicaid rate-setting, risk adjustment, and benefit requirements can pressure profitability and forecastability.
  • Medical cost trend and risk selection: Higher-than-expected utilization, adverse selection, or changes in provider pricing can widen the gap between estimated and realized costs.
  • PBM and pricing policy scrutiny: Pharmacy-related regulation and payer-provider reimbursement dynamics can affect services economics and formulary strategies.
  • Provider market dynamics: Provider consolidation and pricing power can increase cost pressure; network adequacy and contracting execution become more consequential.
  • Operational and cybersecurity risk: Integrated platforms rely on robust systems, data governance, and secure operations; disruptions can impair service quality and lead to regulatory exposure.
  • Execution risk in care delivery: Scaling care delivery models requires sustained quality, staffing, and cost discipline to avoid margin dilution.

📊 Valuation & Market View

Healthcare managed-care platforms are typically valued based on earnings durability, member growth and retention, and improvement in medical cost management, rather than pure top-line expansion. Market pricing often reflects the credibility of:

  • Medical loss ratio discipline and the ability to manage utilization and provider reimbursement over cycles.
  • Services margin expansion driven by Optum scale, operating leverage, and pharmacy/analytics effectiveness.
  • Regulatory sensitivity—the perceived likelihood that reimbursement and policy changes remain within a manageable range.

The valuation “needle movers” are largely tied to forecast accuracy for risk adjustment and medical cost trend, plus the consistency of services execution that converts integrated capabilities into stable cash generation.

🔍 Investment Takeaway

UnitedHealth Group combines a large managed-care membership base with a scaled services platform to form an integrated ecosystem. The principal moat is structural: switching costs, cost advantages from scale, and end-to-end coordination through analytics and services. With demographic-driven demand and continued migration toward managed and value-based care, the long-term thesis rests on sustained utilization management, resilient regulatory navigation, and ongoing Optum execution that reinforces payer economics.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"UNH reported Revenue of $111.7B and Net Income of $6.28B in the latest quarter (EPS $6.90). QoQ, Revenue declined to $111.7B from $113.2B (−1.3%), while Net Income improved sharply from $0.01B in 2025-12-31 to $6.28B. YoY, Revenue grew modestly from $109.6B (2025-03-31) to $111.7B (+2.0%), and Net Income increased from $6.29B to $6.28B (~flat, −0.2%). Over the 4-quarter window, profitability looks volatile, with a major trough in 2025-12-31 (likely non-recurring items), but the most recent quarter shows normalization. On balance sheet, Total Assets rose to $312.6B (+1.0% QoQ), while Total Equity increased to $105.3B (+3.6% QoQ). Net Debt was broadly stable-to-improving at $49.9B (down from $54.0B YoY). The dividend is steady but modest: dividend yield is ~0.81% in the latest quarter, with a payout ratio ~32%. Total shareholder returns are pressured by weak price momentum: 1Y change is −44.5% and 6M is −9.0%, which overwhelms the low dividend yield. Analyst consensus price targets ($374) imply upside vs the current price (~+15%)."

Revenue Growth

Neutral

QoQ Revenue: $113.2B → $111.7B (−1.3%). YoY Revenue: $109.6B → $111.7B (+2.0%). Growth is positive but modest.

Profitability

Fair

Net Income rebounded QoQ from ~$0.01B (2025-12-31) to $6.28B (2026-03-31). YoY Net Income is roughly flat (−0.2%). Margins appear volatile given the outlier quarter.

Cash Flow Quality

Neutral

Net income strength in the latest quarter supports dividends. Dividend payout ratio is ~32% with a stable $2.21 quarterly payment; no buyback data provided.

Leverage & Balance Sheet

Positive

Total Assets are slightly higher QoQ ($309.6B → $312.6B). Equity improved (+3.6% QoQ). Net Debt improved YoY ($54.0B → $49.9B), suggesting resilience.

Shareholder Returns

Neutral

Price momentum is weak: 1Y change −44.5% (major headwind). Dividend yield is low (~0.81%), so total return is likely negative despite shareholder-friendly stability.

Analyst Sentiment & Valuation

Fair

Consensus target is $378 vs current ~$324.6 (roughly +16% upside). However, trailing P/E metrics appear distorted by the 2025-12-31 earnings trough.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

UNH delivered a strong Q1 2026: adjusted EPS of $7.23 and $111.7B revenues (+2% YoY) with a lower medical care ratio (83.9% vs 84.8% a year ago). Management attributes the improvement to pricing discipline, cost management, and favorable reserve development, while acknowledging utilization remains elevated and cohort seasonality effects persist. Optum Health’s outperformance appears tied to prior-period restatement concentrated in markets where clinical reviews and transitions-of-care navigation were intensified, alongside operational execution (standardized scheduling; patient-facing hours +12% YoY). Optum Rx and Optum Insight show measurable productivity/administrative burden reductions from AI-enabled prior auth and automation, supporting longer-term value-based care and AI modernization (nearly $1.5B targeted in 2026). Guidance was refreshed to >$18.25 adjusted EPS, but the setup is mixed: Medicaid remains at negative margins with funding/rate headwinds extending into 2027, and Medicare Advantage 2027 sustainability depends on closing the gap between elevated medical trend and funding levels.

AI IconGrowth Catalysts

  • UnitedHealthcare: pricing improving vs elevated cost trends; affordability initiatives generating positive momentum
  • UHC digital adoption: almost half of members registered for UHC digital access; 73 million digital visits in Q1 (+42% vs last 2 years); digital-first contact mix (>80% of consumer contacts)
  • Optum Health: return to disciplined, integrated value-based care model; stronger clinical and medical management driving fewer unnecessary inpatient/SNF admissions
  • Optum Health West region: data-driven clinical navigation for admission/discharge, SNF transitions, and ED encounters; clinical reviews increased >50%
  • Optum Health fee-for-service: standardized scheduling guidelines and analytics; patient-facing hours up 12% YoY
  • Optum Rx: PreCheck Prior Authorization capability reducing approval time from >8 hours to <30 seconds; 68% reduction in denial due to missing information; 88% reduction in appeals
  • Optum Insight: AI-first products gaining traction; Optum Real reducing manual contact costs by 76%

Business Development

  • Optum Financial Services agreed to acquire Alegeus Technologies; expected to be accretive in 2027
  • Network partnerships between rural providers and leading regional health systems (to improve access for rural clinicians/providers)
  • UnitedHealthcare accelerated payments for rural hospitals and exempt rural health care providers from most medical prior authorization requirements (rural payment and network initiatives)

AI IconFinancial Highlights

  • Adjusted EPS $7.23 in Q1 2026, well ahead of expectations; exceeded plan across all segments
  • Total revenues $111.7B, +2% YoY, driven by disciplined pricing and member mix
  • Reported medical care ratio 83.9% vs 84.8% in Q1 2025; improved due to pricing discipline, medical cost management, and favorable reserve development
  • Operating cost ratio 13.8% (timing of targeted investments across operations/technology/care delivery plus AI, customer experience, cybersecurity, and community engagement)
  • Incentive compensation recorded ~$900M in Q1 vs ~$35M in Q1 2025 (performance-driven)
  • Operating cash flow $8.9B in the quarter (1.4x net income)
  • Medical cost ratio pacing: Q1 levels >250 bps below full-year midpoint guidance; second-half expected >200 bps above midpoint (earnings/cost cadence discussion)
  • Updated full-year outlook to >$18.25 adjusted EPS per share
  • Medicaid expectations: membership attrition and negative margins in 2026, with modest margin improvements beginning 2027; state rate processes open into 2027
  • Share repurchases: initiated earlier than anticipated; deploy at least $2B by end of Q2
  • Non-operating/residual impacts removed from 2026 adjusted results: net negative ~$50M for the quarter (includes $525M gain on sale of the U.K. business; $400M of proceeds to United Health Foundation)

AI IconCapital Funding

  • Debt-to-capital ratio improved to 42.9% (on track for 40% year-end goal)
  • Expect at least $2B share repurchases deployed by end of Q2 2026
  • Strategic acquisition funding expected to continue (measured while prudently managing balance sheet)
  • Used $400M of U.K. business sale proceeds to provide additional funding to United Health Foundation

AI IconStrategy & Ops

  • Exited non-U.S. businesses; refocused organization squarely on U.S. health care
  • Refreshed nearly half of top 100 leadership roles
  • Accelerated AI-enabled modernization: on track to invest nearly $1.5B in AI-related initiatives in 2026
  • Prior authorization operations: ~95% submitted electronically; ~50% processed in real time; >90% approved on average in 1 business day; working to reduce overall number of medical prior authorizations by 30%+ by end of 2026
  • Digital self-service: primary member interaction channel; >80% consumer contacts through digital formats; transaction volumes up 75% YoY; ~75% of in-network providers using portal or API tools
  • Optum Health operating transformation: standardized workflows across ~70% of settings, targeting nearly 80% by end of Q2; scheduling guided by AI-enabled tools
  • Optum Insight/Optum Rx: expanded digital/AI self-service to reduce operational burdens (Optum Rx call center volume down 25%; PreCheck speeds and denial/appeal reductions)

AI IconMarket Outlook

  • Full-year updated guidance: greater than $18.25 adjusted EPS per share
  • Earnings cadence unchanged: ~2/3 of earnings in first half, ~1/3 in second half
  • Medicare MA trend framing: pricing posture supported by early-year results; will provide more detailed category view in Q2
  • Membership: expected total membership contract in 2026 centered around ~1.3 million drop; ACA continues to contract with expectation total membership decline of approximately 1/3 in 2026; Q1 results reflect refund pledge for 2026 ACA profits
  • Medicare MA long-term margin recovery: path to margin recovery within 2% to 4% long-term range; aspiration for 2027 to be in upper half of 2% to 4% range

AI IconRisks & Headwinds

  • Medicaid: high medical trend plus insufficient funding leading to membership attrition and negative margins in 2026; state rate processes remain open into 2026 and into 2027
  • Underlying utilization remains at high elevated levels consistent with 2025; risk of continued elevated service intensity and provider billing patterns
  • Medicare MA funding/trend mismatch: widely expected 2027 medical trend still meaningfully above funding levels despite improved CMS final notice alignment
  • IRA-related changes: impact to Part D seasonality shifted earnings profile beginning 2025; causes earnings cadence volatility
  • Drug pricing increases and increasing complexity in specialty drugs (specialty drugs >50% of drug spend) increasing pressure on affordability and trends

Q&A: Analyst Interest

  • Trend sizing for Medicare Advantage: Analysts asked whether 2026 cost trend is closer to ~10% pricing assumptions or the historical ~7%–8%. Management responded that early-year trend is progressing in line with expectations, with modest favorability in government programs and no inflection; full category detail planned for Q2.
  • Optum Health outperformance drivers and pacing: Analysts requested how much Q1 Optum Health improvement is prior-year reserve development versus utilization/contract changes, and why most earnings are in the first half. Management said improvement is driven by favorable prior periods concentrated in markets with intensified clinical management, plus operating execution gains like scheduling that increased patient-facing hours.
  • Medicare Advantage margin recovery confidence for 2027 and BALANCE participation thresholds for GLP-1s: Analysts asked about confidence in further margin recovery and whether UNH will participate in CMS’s BALANCE program for GLP-1s. Management framed 2027 as still threatened by medical trend above funding levels and stated aspirations within the 2%–4% long-term margin range, with further details likely after more specifics.

Sentiment: MIXED

Note: This summary was synthesized by AI from the UNH Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for UNH.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (UNH)

© 2026 Stock Market Info — UnitedHealth Group Incorporated (UNH) Financial Profile